In this episode, Nimish Gera, Vice President of Biologics at Mythic Therapeutics, talks about the work Mythic Therapeutics does and the role LabOps play in it.
Nimish is the scientific co-founder of Mythic, where he oversees the discovery of “antibodies”; These molecules target chemotherapy to a certain area, killing intended cells and minimizing toxicities.
With a chemical engineering background, he started working at the lab himself and realized that LabOps personnel are the ones who do critical day-to-day tasks that allow the developments to happen. Finally, he talks about how as a leader he keeps an eye on the use of lab resources and ensures he’s including and motivating LabOps employees.
Tune in to this episode to listen to what Nimish Gera has learned working at Mythic Therapeutics about LabOps in cancer biologics development!
Lab Operations are the foundation for scientific work at Mythic Therapeutics.
About Nimish Gera:
Nimish Gera, Ph.D., is the Vice President of Biologics at Mythic Therapeutics overseeing antibody discovery, engineering, optimization, and cell-based screening technologies to generate antibody-drug conjugates. Nimish’s broad experience in biotech encompasses various modalities (monoclonal antibodies, bispecific antibodies, protein-fusions, and antibody-drug conjugates) and therapeutic areas (oncology, immuno-oncology, autoimmune, and rare disease). Prior to Mythic, Nimish served as a project leader at Alexion Pharmaceuticals, where he led and managed diverse cross-functional project teams to lead two antibody discovery programs into development. Prior to Alexion, Nimish helped establish discovery sciences functionality at Oncobiologics (now Outlook Therapeutics) and identified multiple lead candidates for the company’s platform. He earned a Ph.D. in Chemical and Biomolecular engineering with a minor in biotechnology at North Carolina State University and a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Guwahati.
Things You’ll Learn:
Mythic Therapeutics ensures that the antibody molecule they use can kill the targeted tumor and not affect the normal tissues.
Many chemical engineers end up in process development, manufacturing the antibody molecule and scaling it up.
During the last two years, in the pandemic, it’s been quite difficult to get lab resources from a supply chain perspective.
To move science forward, it’s really important to have the scientists working directly with LabOps, ensuring good communication and that the work is not too siloed.
We still need to figure out a way to minimize the plastic waste we generate in science.
When you understand the reason why you’re needed in the research as a LabOps employee, you’re more likely to be more involved with it and be more motivated.